Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?
Mené aux Etats-Unis entre 2017 et 2020 sur 156 patients atteints d'un cancer du poumon non à petites cellules de stade précoce, cet essai randomisé de phase II compare l'efficacité, du point de vue de la réponse pathologique majeure, et la toxicité d'un traitement par durvalumab en monothérapie néoadjuvante par rapport à un traitement associant le durvalumab et une radiothérapie stéréotaxique
The testing of new neoadjuvant therapeutic strategies for operable non-small-cell lung cancer (NSCLC) has rapidly progressed as it has benefitted from the practice-changing results that have emerged from trials of immune checkpoint inhibitors in the metastatic setting. To date, more than 20 clinical trials have tested immune checkpoint inhibitors either as monotherapy, in combination with anti-CTLA-4, or in combination with chemotherapy. Several of these studies have used major pathological response as one of the main outcomes.
The Lancet Oncology , commentaire, 2020